November 2, 2015 — Seeking to get its first drug ready for human testing, San Diego biotech Crinetics Pharmaceuticals has raised $40 million in venture capital funding. Crinetics is developing a drug to treat acromegaly, a rare endocrine disorder caused by overproduction of human growth hormone in adults. It can raise the risk of several diseases, including type 2 diabetes, cardiovascular disease, arthritis, erectile dysfunction and menstrual abnormalities. Read the full article here.

 

Investors:
Gayathri Diwakar
Head of Investor Relations
[email protected]
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
[email protected]
(858) 450-6464